Nanostructured lipid carriers based mRNA vaccine leads to a T cell-inflamed tumour microenvironment favourable for improving PD-1/PD-L1 blocking therapy and long-term immunity in a cold tumour model - eBioMedicine | Carole Fournier, Cnrs Umr, CHU Grenoble Alpes

Nanostructured lipid carriers based mRNA vaccine leads to a T cell-inflamed tumour microenvironment favourable for improving PD-1/PD-L1 blocking therapy and long-term immunity in a cold tumour model - eBioMedicine

Jan 09, 2025 |

By Carole Fournier, Cnrs Umr, CHU Grenoble Alpes

| EBioMedicine

Keywords mRNA vaccine Immune checkpoint inhibitor Cancer T cells Innate immunity Memory immunity Abbreviations APC, antigen presenting cell (BMDC, bone marrow dendritic cell) DC, dendritic cell (FMO, fluorescence minus one) GSEA, gene set enrichment analysis (ICB, immune checkpoint blockade) ICI, immune checkpoint inhibitor (IHC, immunohistochemistry) I.P, intraperitoneal (KEGG, kyoto encyclopedia of genes and genomes) LNP, lipid nanoparticle (NLC, nanostructured lipid carrier) OVA, ovalbumin...

Open in Who Shared

For PR Teams

Overview

Use Cases

Capabilities

Industries

Introducing Curation Engine

Resources

Library

Commmunity

Customers

Company

Nanostructured lipid carriers based mRNA vaccine leads to a T cell-inflamed tumour microenvironment favourable for improving PD-1/PD-L1 blocking therapy and long-term immunity in a cold tumour model - eBioMedicine